MY163014A - Kappa selective opioid receptor antogonist - Google Patents
Kappa selective opioid receptor antogonistInfo
- Publication number
- MY163014A MY163014A MYPI2010003437A MYPI2010003437A MY163014A MY 163014 A MY163014 A MY 163014A MY PI2010003437 A MYPI2010003437 A MY PI2010003437A MY PI2010003437 A MYPI2010003437 A MY PI2010003437A MY 163014 A MY163014 A MY 163014A
- Authority
- MY
- Malaysia
- Prior art keywords
- opioid receptor
- selective opioid
- antogonist
- kappa selective
- kappa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY163014A true MY163014A (en) | 2017-07-31 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010003437A MY163014A (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antogonist |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7709522B2 (OSRAM) |
| EP (1) | EP2252581B1 (OSRAM) |
| JP (1) | JP5345637B2 (OSRAM) |
| KR (1) | KR101172170B1 (OSRAM) |
| CN (1) | CN101925576B (OSRAM) |
| AR (1) | AR070158A1 (OSRAM) |
| AU (1) | AU2009206653B2 (OSRAM) |
| BR (1) | BRPI0907382B8 (OSRAM) |
| CA (1) | CA2713025C (OSRAM) |
| CO (1) | CO6290644A2 (OSRAM) |
| CY (1) | CY1113071T1 (OSRAM) |
| DK (1) | DK2252581T3 (OSRAM) |
| DO (1) | DOP2010000222A (OSRAM) |
| EA (1) | EA017484B1 (OSRAM) |
| EC (1) | ECSP10010365A (OSRAM) |
| ES (1) | ES2388708T3 (OSRAM) |
| HR (1) | HRP20120558T1 (OSRAM) |
| IL (1) | IL206038A (OSRAM) |
| JO (1) | JO2797B1 (OSRAM) |
| MA (1) | MA32751B1 (OSRAM) |
| MX (1) | MX2010007849A (OSRAM) |
| MY (1) | MY163014A (OSRAM) |
| NZ (1) | NZ586225A (OSRAM) |
| PE (1) | PE20091317A1 (OSRAM) |
| PL (1) | PL2252581T3 (OSRAM) |
| PT (1) | PT2252581E (OSRAM) |
| SI (1) | SI2252581T1 (OSRAM) |
| TN (1) | TN2010000306A1 (OSRAM) |
| TW (1) | TWI422369B (OSRAM) |
| UA (1) | UA100715C2 (OSRAM) |
| WO (1) | WO2009094260A1 (OSRAM) |
| ZA (1) | ZA201003908B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907230A2 (pt) * | 2008-01-22 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto |
| CN101925576B (zh) * | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| EP2757881A4 (en) | 2011-09-15 | 2014-11-12 | Univ Kansas | KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF |
| US10813925B2 (en) | 2011-09-19 | 2020-10-27 | Carmel—Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| CA2858752C (en) | 2011-12-09 | 2019-12-31 | Research Triangle Institute | 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| JP2016519161A (ja) * | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| EP4574210A3 (en) | 2017-03-17 | 2025-10-15 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| IL308221A (en) | 2021-05-04 | 2024-01-01 | Janssen Pharmaceuticals Inc | Preparations and methods for treating depression |
| IL314179A (en) * | 2022-01-10 | 2024-09-01 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
| US20250064779A1 (en) * | 2022-01-10 | 2025-02-27 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156210A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 纯形式的结晶阿替卡普兰 |
| EP4489730A1 (en) * | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) * | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| JP3706307B2 (ja) * | 1999-05-12 | 2005-10-12 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾジアゼピン誘導体 |
| WO2002029418A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) * | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| US7119196B2 (en) * | 2002-03-28 | 2006-10-10 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| ES2392200T3 (es) * | 2002-09-19 | 2012-12-05 | Eli Lilly & Company | Ésteres de diarilo como antagonistas del receptor opiáceo |
| DE602004016127D1 (de) * | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| AU2004220112A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| BRPI0417156A (pt) * | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| JP2007516284A (ja) * | 2003-12-22 | 2007-06-21 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| CA2559207A1 (en) * | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| DE602005022572D1 (de) * | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ATE399164T1 (de) * | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ES2318472T3 (es) * | 2004-03-15 | 2009-05-01 | Eli Lilly And Company | Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad. |
| EP1735268B1 (en) * | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DK2001456T3 (da) | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| CN101925576B (zh) * | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
-
2009
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY163014A (en) | Kappa selective opioid receptor antogonist | |
| EP2350789A4 (en) | PROXIMITY INTERFACE DEVICES, SYSTEMS AND METHOD | |
| EP2516311A4 (en) | ELEVATOR, RAIL-GUIDE FASTENING BRACKET, ARRANGEMENT AND METHOD | |
| ZA201006587B (en) | Methods for treating disorders using nmda nr2b-subtype selective antagonist | |
| GB2475009B (en) | Method and system for storing,delivering and spooling preassembled pipelines | |
| EP2261496A4 (en) | FUEL SUPPLY DEVICE | |
| EP2379140A4 (en) | NEEDLE GUIDE | |
| PL2331451T3 (pl) | Czerpalna głowica, nalewające urządzenie i sposób stosowania nalewającego urządzenia | |
| SG136908A1 (en) | Guide device, particularly for use in welding | |
| PL2682485T3 (pl) | Sposób i urządzenie do wytwarzania rur stalowych o szczególnych właściwościach | |
| SI2174570T1 (sl) | Kotalno izvlečno vodilo | |
| GB2474977B (en) | Hydrocarbon production system, method for performing clean-up and method for controlling flow | |
| EP2259609A4 (en) | METHOD, SYSTEM AND DEVICE FOR CONVERSATION | |
| IL207700A0 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists | |
| GB2464489B (en) | Pipe clip | |
| IL207701A0 (en) | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists | |
| AP2011005547A0 (en) | Method and device for core drilling. | |
| FR2934005B1 (fr) | Dispositif de guidage pour occulteur a rideau | |
| PT2234751T (pt) | Processo e dispositivo para soldadura de estruturas de assentos, e assentos | |
| EP2364955A4 (en) | NITRATE ELIMINATING BIOREACTOR, METHOD FOR FORMING NITRATE ELIMINATING BIOFILM, AND METHOD FOR REMOVING NITRATES | |
| EP2059644A4 (en) | DEVICE FOR A GUIDE RAIL | |
| GB201015539D0 (en) | Pipe alignment device | |
| CR11559A (es) | Antagonista del receptor opioide selectivo kappa | |
| PL382804A1 (pl) | Sposób oprowadzania oraz urządzenie do oprowadzania, zwłaszcza turystów | |
| GB2473783B (en) | Guide part device |